Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
32.81
+0.16 (+0.49%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
August 21, 2023
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,
Via
Benzinga
Exposures
Product Safety
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs
Via
Benzinga
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
August 21, 2023
The biotech's focus on innovation could be a boon for shareholders.
Via
The Motley Fool
What's Going On With Sonnet BioTherapeutics Stock Today?
August 16, 2023
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 (IL12-FHAB) in combination with Roche...
Via
Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
August 14, 2023
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.
Via
Investor's Business Daily
Why Novartis Stock Spiked Today
July 18, 2023
A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today.
Via
The Motley Fool
Stock Analysis: Roche Holding AG
May 16, 2023
Roche is a Swiss biopharmaceutical and diagnostic company.
Via
Talk Markets
Is TTOO Stock Really Worth $5? Or Just 5 Cents?
August 09, 2023
TTOO stock has been red hot in recent days, but the story of MULN stock should give speculative investors in T2 Biosystems caution.
Via
InvestorPlace
Is AbbVie Still a Good Dividend Stock to Buy?
August 08, 2023
Find out if AbbVie can overcome sinking sales of its top-selling product.
Via
The Motley Fool
Why Is Aravive Stock Sinking Today?
August 03, 2023
Aravive Inc (NASDAQ: ARAV) shares plunged after the company's Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary...
Via
Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.
Via
Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
July 26, 2023
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen
Via
Benzinga
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
July 24, 2023
Wall Street Journal
Via
Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
July 24, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to
Via
Benzinga
Q2 Earnings Scorecard And Analyst Reports
July 18, 2023
We now have Q2 results from 38 S&P 500 members.
Via
Talk Markets
2 Nasdaq Stocks That Could Soar This Week
July 16, 2023
BridgeBio Pharma and Roivant Sciences could make big moves this week.
Via
The Motley Fool
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories
July 14, 2023
Benzinga
Via
Benzinga
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover
July 14, 2023
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed.
Via
Investor's Business Daily
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
July 14, 2023
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)
Via
Benzinga
How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg
July 13, 2023
The companies are rivals in the multiple sclerosis treatment realm with Ocrevus and Briumvi.
Via
Investor's Business Daily
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
July 13, 2023
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...
Via
Benzinga
Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate
June 28, 2023
Blue Water Biotech Inc (NASDAQ: BWV) has released preliminary preclinical data that supports the potential use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for the...
Via
Benzinga
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma
June 16, 2023
The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)...
Via
Benzinga
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
June 14, 2023
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and
Via
Benzinga
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
June 09, 2023
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e
Via
Benzinga
Why Shares of Zentalis Pharmaceuticals Dropped This Week
June 02, 2023
A rash of insider selling meant the stock gave back some of its gains from last week.
Via
The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
May 26, 2023
Roche tested its treatment in patients with liver cancer and found "meaningful" results.
Via
Investor's Business Daily
Why Shares of Rain Oncology Are Plummeting Today
May 22, 2023
The company released disappointing top-line results for its lead oncology therapy.
Via
The Motley Fool
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
May 17, 2023
Benzinga
Via
Benzinga
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
May 17, 2023
Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.